Skymount Medical

05/31/2022

We are honored to be recognized for achievement in the Artificial Intelligence and Machine Learning Solution category with a Silver win in the prestigious 20th Annual American Business Awards®.
Read more here: https://bit.ly/38U48zh

LSU Research The Stevie Awards

02/22/2022

Skymount Medical announced today that it has achieved a significant milestone with the recent approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a human clinical trial of its novel oral therapeutic for patients with mild to moderate COVID-19. Read the full announcement here: https://bit.ly/3p8kaKC

LSU LSU Research

-- MHRA grants permission for UK clinical trials for AI-discovered drug combination that reduces length and severity of symptoms and could lower...

02/04/2022

Our Chief Medical and Scientific Officer, Kishor Wasan, explains how our team is facilitating accelerated drug identification, safety studies, and clinical trials in partnership with academia. Learn more here. https://bit.ly/3sl7YHn

LSU Research

AI Gives the Pharmaceutical Industry Focus, Kishor Wasan Says

01/20/2022

Skymount Medical is fighting COVID-19 in partnership with LSU Research and the LSU-developed artificial intelligence. Read more about how the DeepDrug technology, developed by LSU researchers, is resulting in the discovery of new treatments, faster and cheaper.
https://bit.ly/3tKIGof

Biotech innovation is about understanding living systems at their deepest and smallest levels and then translating that knowledge to engineer new results.

01/17/2022

A recent MarketScale interview with our Chief Medical and Scientific Officer, Kishor Wasan, on the FDA's accelerated or fast-tracked COVID-19 pill approval process and why this emergency use authorization pathway is drawing so much attention now. Learn more here. https://bit.ly/3noVVab

In late December, the U.S. Food and Drug Administration approved Emergency Use Authorization of Pfizer's Paxlovid, a pill to help treat COVID-19. The next day a

12/16/2021

An exclusive interview featuring our Chief Medical & Scientific Officer was recently published in the Pharmafile Autumn 2021 edition, page 8. They discuss DeepDrug, how AI is supporting new therapeutic combinations, and explore how AI can help to bring drugs to the people who need it most.
Read more in the magazine's Q&A section. https://bit.ly/3pYuog7

11/18/2021

Listen to our Chief Executive Officer and Chief Medical & Scientific Officer as they discuss clinical trials, breakthroughs on COVID-19 treatments, and how AI tech is disrupting drug discovery and development, in an earlier interview with Danielle Smith, President of Alberta Enterprise Group.
Check it out here: https://youtu.be/lFsT4BUxYhc

Join Danielle Smith and executives from Skyview for a discussion on clinical trials and medical innovation

11/12/2021

Our DeepDrug and Skymount Medical team's recent paper in Drug Discovery Today has now been listed as part of the Public Health Emergency COVID-19 Initiative! Learn more here. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570449/

11/06/2021

Our DeepDrug™ and Skymount Medical team has published a paper in Drug Discovery Today!
In this review, they investigate the technologies at the forefront of spearheading an AI revolution in drug discovery and pharmaceutical sciences.

The search for effective drugs to treat new and existing diseases is a laborious one requiring a large investment of capital, resources, and time. The…

11/03/2021

New Flash | Skymount Medical has partnered with Riverside University Health System (RUHS) Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by Louisiana State University researchers using artificial intelligence.

Read the full press release at: https://skymountmed.com/2021/11/03/riverside-university-health-system-medical-center-skymount-medical-begin-u-s-clinical-trial-for-covid-19-oral-therapeutics-discovered-using-artificial-intelligence/

10/23/2021

Our new, breakthrough nutraceutical brand, Inhibinol is a proud sponsor of in Austin this weekend for the Big Race.

Sports Illustrated

10/15/2021

MarketScale gets insight from our Chief Medical and Scientific Officer, Dr. Kishor M. Wasan, on how federal initiatives helped to jump start early efforts with research and innovation, including highlights of the development of DeepDrug™. Read more: https://marketscale.com/industries/sciences/what-can-the-pharma-industry-learn-from-mercks-new-antiviral/

  Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of m